Back

Regression of cardiac amyloid deposits with novel therapeutics: reaching new frontiers in cardiac ATTR amyloidosis

29 August 2020 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Advances in the Diagnosis and Treatment of Cardiac Amyloidosis Infiltrative Myocardial Disease ESC Premium Access ESC Congress 2020

About the speaker

Photo
Doctor Liza Chacko

University College Hospital, London (United Kingdom of Great Britain & Northern Ireland)

6 More presentations in this session

Presentation thumbnail
Prognostic impact of suspected cardiac amyloidosis in aortic stenosis patients referred for transcatheter aortic valve implantation
Doctor V. Ferreira (Lisbon, PT)
Abstract Slides
Presentation thumbnail
Hereditary transthyretin amyloidosis: predictors of conduction disease
Doctor A. Dias De Frias (Porto, PT)
Abstract Slides
Presentation thumbnail
High-sensitivity cardiac troponin T and NT-proBNP for ruling-in and ruling-out of cardiac amyloidosis
Doctor V. Castiglione (Pisa, IT)
Abstract Slides
Presentation thumbnail
Regional cardiac uptake of 99-Tc-DPD is a novel powerful and independent prognostic marker in cardiac ATTR wild type amyloidosis.
Doctor P. Milani (Pavia, IT)
Abstract Slides
Presentation thumbnail
Benefits of tafamidis in patients with advanced transthyretin amyloid cardiomyopathy
Doctor C. Rapezzi (Ferrara, IT)
Abstract Slides

Access the full session

Session thumbnail
Advances in the Diagnosis and Treatment of Cardiac Amyloidosis

The Event

Event poster

ESC Congress 2020

29 August - 1 September 2020

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources